Drug Profile
GRT 6010
Alternative Names: GRT-6010Latest Information Update: 02 Mar 2021
Price :
$50
*
At a glance
- Originator Grunenthal
- Class Analgesics; Antiallergics
- Mechanism of Action Nociceptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain; Pain
Most Recent Events
- 02 Mar 2021 Discontinued - Phase-II for Pain in Poland, Germany (Intravesicular)
- 02 May 2018 Grunenthal completes a phase II trial in Pain in Germany and Poland (Intravesicular) (EudraCT2016-003940-35)
- 25 May 2017 Phase-II clinical trials in Pain in Poland (Intravesicular) (EudraCT2016-003940-35)